Between Jan 2010 and Feb 2012 patients in the CROES renal mass registry cohort were included in this study. All included patients were with either cTla (n=1713) or >cT1b (n=1819), Only patients who were NX/0 and M0 were included in the study. The RCC pTla and >pT1b cohorts consisted of 1194 and 1380 patients respectively. The 2009 TNM classification stage was used. Age, gender, ethnicity, BMI, comorbidities , risk factors, and history of RCC were compared between the two cohorts.
Patients with a cT1a tumors were more commonly Caucasian (p=0.049), had more comorbidities (p=0.001), and a higher rate of risk factors (p=0.002). Median pre-operative Creatinine value was lower in the cTla cohort (p=0.032) and a higher number of patients had advanced CKD stage (>III) in the cT1b cohort (p=0.002). In the cT1a cohort the tumor was predominantly discovered as an incidental finding compared to >cT1b (83.8% vs. 62.1% p<0.001). A solitary kidney was more frequently encountered in the cTla cohort.. Out of the cT1a cases 13.9% were pathologically upstaged mostly to pT3a. Conversely 13.8% of >cT1b cases were pathologically downstaged to pT1a.
When comparing between RCC pTla vs. pT1b and above, a significant difference in risk factors (p=0.014), advanced CKD (p=0.018), incidental finding (p<0.001), and solitary kidney (p=0.002) was demonstrated. Furthermore, a significant difference was observed between pT1a and >pT1b for mean age (60.0 vs. 61.7, p=0.001).
The authors concluded that differences between cT1a and >cT1b tumors were found for ethnicity, comorbidities, and pre-operative creatinine values. RCC patients in the pTla cohort were younger than in the >pT1b cohort.
Presented by: Bernhard JCl
Affiliation: Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal